idebenone has been researched along with Chronic Progressive Multiple Sclerosis in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Idebenone was well tolerated but did not inhibit disability progression or CNS tissue destruction." | 2.94 | Idebenone does not inhibit disability progression in primary progressive MS. ( Bielekova, B; Komori, M; Kosa, P; Leinonen, M; Masvekar, R; Phillips, J; Sandford, M; Wichman, A; Wu, T, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kosa, P | 1 |
| Wu, T | 1 |
| Phillips, J | 1 |
| Leinonen, M | 1 |
| Masvekar, R | 1 |
| Komori, M | 1 |
| Wichman, A | 1 |
| Sandford, M | 1 |
| Bielekova, B | 1 |
| Dolgin, E | 1 |
1 trial available for idebenone and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Idebenone does not inhibit disability progression in primary progressive MS.
Topics: Axons; Biomarkers; Disease Progression; Double-Blind Method; Humans; Multiple Sclerosis; Multiple Sc | 2020 |
1 other study available for idebenone and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Therapies: Progressive steps.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, CD20; Azetidines; B-Lymphocytes; Benzamides; B | 2016 |